TITLE

Cancer: Preserving fertility during chemotherapy

AUTHOR(S)
Charlotte, Harrison
PUB. DATE
July 2013
SOURCE
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p506
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the effect of anticancer drug cyclophosphamide on fertility, referencing a study by L. Kalich-Philosoph et al published in a 2013 issue of "Science Translational Medicine."
ACCESSION #
88783765

 

Related Articles

  • Tocotrienol preserves ovarian function in cyclophosphamide therapy. Saleh, H. S.; Omar, E.; Froemming, G. R. A.; Said, R. M. // Human & Experimental Toxicology;Oct2015, Vol. 34 Issue 10, p946 

    Introduction: Cyclophosphamide (CPA) chemotherapy leads to ovarian failure and infertility. Tocotrienol (T3) is an antioxidant and anti-inflammatory agent. The role of T3 in ovarian protection throughout chemotherapy remains unclear. Aim: To investigate the role of T3 in the preservation of...

  • Un désir qui devient réalité: grossesse après chimiothérapie d'un cancer du sein. Joly, C.; Weber, B. // Oncologie;Jun2012, Vol. 14 Issue 6/7, p433 

    Pregnancy after a chemotherapy for breast cancer is no longer a rare event. The example of two women who started a spontaneous pregnancy after a chemotherapy proves it. Patient education, better knowledge of medicines and their side effects as well as the possibilities of assisted reproduction...

  • Conference Abstracts.  // Fertility Weekly;4/7/2014, p13 

    The article presents abstracts on fertility which include the increased risk of breast cancer after multiple implantation of in vitro fertilization (IVF), cyclophosphamide, and cryopreservation method for very low human spermatozoa count.

  • Ciclosporin/cyclophosphamide/methotrexate.  // Reactions Weekly;6/19/2010, Issue 1306, p16 

    The article describes the case of a 15-year-old girl with myelodysplastic syndrome who was diagnosed with reversible posterior leukoencephalopathy syndrome (RPLS) after taking ciclosporin, cyclophosphamide and methotrexate.

  • Cyclophosphamide/enalapril.  // Reactions Weekly;4/7/2012, Issue 1396, p17 

    The article describes the case of a 56-year-old woman who experienced acute hyponatraemia with a generalized seizure during treatment with cyclophosphamide and enalapril for invasive ductal carcinoma of the right breast and hypertension, respectively.

  • Adjuvant TAC may improve survival in women with node-negative breast cancer.  // Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p45 

    The article reports on a study which revealed the potential of doxetacel, doxorubicin and cyclophosphamide in improving survival in women with node-negative breast cancer.

  • Regimen appears effective for patients with HER-2-amplified early breast cancer. Cox, Amber; Kalvaitis, Katie; Southall, Jennifer // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p30 

    The article presents the results of an open-label phase two study as of October 2013, which showed that four cycles of docetaxel and cyclophosphamide plus one year of trastuzumab could be an efficient adjuvant treatment regimen for females with lower-risk HER-2-amplified early breast cancer.

  • Antithymocyte globulin/busulfan/cyclophosphamide.  // Reactions Weekly;5/21/2011, Issue 1352, p11 

    The article describes the case of a 14-year-old female stem-cell transplant recipient who developed hepatic sinusoidal obstruction syndrome after receiving treatment with antithymocyte globulin, busulfan and cyclophosphamide.

  • Antineoplastics.  // Reactions Weekly;9/8/2012, Issue 1418, p11 

    The article describes the case of a female patient who developed paraneoplastic pemphigus while being treated with fludarabine and cyclophosphamide (FC) for chronic lymphocytic leukaemia (CLL).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics